Anemia Management and QOL and Frailty in CKD

2020 ◽  
pp. 239-245
Author(s):  
Mariko Miyazaki
Keyword(s):  
Anemia Management

Risk Factors for Cardiovascular Disease in Patients Undergoing Peritoneal Dialysis

2007 ◽  
Vol 27 (2_suppl) ◽  
pp. 205-209 ◽  
Author(s):  
Elvia García–López ◽  
Juan J. Carrero ◽  
Mohamed E. Suliman ◽  
Bengt Lindholm ◽  
Peter Stenvinkel
Keyword(s):  
Risk Factors ◽  
Peritoneal Dialysis ◽  
Cardiovascular Risk ◽  
Pressure Control ◽  
High Cardiovascular Risk ◽  
Cardiovascular Research ◽  
Factors Associated ◽  
Glycation End Products ◽  
Anemia Management ◽  
Altered Lipid

Patients on peritoneal dialysis (PD) are at high cardiovascular risk. Although some risk factors are unmodifiable (for example, age, sex, genetics), others are exacerbated in the unfriendly uremic milieu (inflammation, oxidative stress, mineral disturbances) or contribute per se to kidney disease and cardiovascular progression (diabetes mellitus, hypertension). Moreover, several factors associated with PD therapy may both increase (by altered lipid profile, hyperinsulinemia, and formation of advanced glycation end-products) and decrease (by better blood pressure control and anemia management) cardiovascular risk. The present review discusses recent findings and therapy trends in cardiovascular research on the PD population, with emphasis on the roles of inflammation, insulin resistance, homocysteinemia, dyslipidemia, vascular calcification, and genetics/epigenetics.

scholarly journals An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost

Anemia ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Geoffrey Teehan ◽  
Robert L. Benz
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Randomized Trials ◽  
Lessons Learned ◽  
Patients With Diabetes ◽  
Anemia Management ◽  
Erythropoietin Deficiency ◽  
Stage Renal Disease ◽  
End Stage

Background. Erythropoietin deficiency and anemia occur in Chronic Kidney Disease (CKD) and may be treated with Erythropoietin Stimulating Agents (ESAs). The optimal hemoglobin, in non-End Stage Renal Disease CKD, is controversial.Methods. We review three recent randomized trials in anemia in CKD: CHOIR, CREATE, and TREAT.Results. CHOIR (N=1432) was terminated early with more frequent death and cardiovascular outcomes in the higher Hb group (HR 1.34: 95% C.I. 1.03–1.74,P=.03). CREATE (N=603) showed no difference in primary cardiovascular endpoints. Stroke was more common in the higher Hb group (HR 1.92; 95% C.I. 1.38–2.68;P<.001) in TREAT (N=4038).Conclusions. There is no benefit to an Hb outside the 10–12 g/dL range in this population. To avoid transfusions and improve Quality of Life, ESAs should be used cautiously, especially in patients with Diabetes, CKD, risk factors for stroke, and ESA resistance.

scholarly journals Associations of pre-transplant anemia management with post-transplant delayed graft function in kidney transplant recipients

2012 ◽  
Vol 26 (5) ◽  
pp. 782-791 ◽  
Author(s):  
Miklos Z. Molnar ◽  
Csaba P. Kovesdy ◽  
Laszlo Rosivall ◽  
Suphamai Bunnapradist ◽  
Junichi Hoshino ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Graft Function ◽  
Delayed Graft Function ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Post Transplant ◽  
Anemia Management

Individualization of pharmacological anemia management using reinforcement learning

2005 ◽  
Vol 18 (5-6) ◽  
pp. 826-834 ◽  
Author(s):  
Adam E. Gaweda ◽  
Mehmet K. Muezzinoglu ◽  
George R. Aronoff ◽  
Alfred A. Jacobs ◽  
Jacek M. Zurada ◽  
...  
Keyword(s):  
Reinforcement Learning ◽  
Anemia Management

scholarly journals Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis

PLoS ONE ◽  
2018 ◽  
Vol 13 (9) ◽  
pp. e0203767 ◽  
Author(s):  
James B. Wetmore ◽  
Suying Li ◽  
Heng Yan ◽  
Hairong Xu ◽  
Yi Peng ◽  
...  
Keyword(s):  
Retrospective Cohort ◽  
Cohort Analysis ◽  
Dialysis Initiation ◽  
Retrospective Cohort Analysis ◽  
Anemia Management

scholarly journals SP347IMPACT OF ORAL ANTICOAGULANT AND ANTIPLATELET THERAPIES ON ANEMIA MANAGEMENT: EXPERIENCE OF NEPHROCARE FRANCE

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i462-i462
Author(s):  
Charles Chazot ◽  
Bernard Canaud ◽  
Claudio Ferrari ◽  
Marzio Alunni ◽  
Stefano Stuard
Keyword(s):  
Oral Anticoagulant ◽  
Anemia Management ◽  
Management Experience

Anemia Management

2008 ◽  
pp. 337-356
Author(s):  
Arthur Tsai ◽  
Jeffrey S. Berns
Keyword(s):  
Anemia Management

scholarly journals The effect of anemia management on chronic renal failure progression

2013 ◽  
Vol 61 (1) ◽  
pp. 37-41 ◽  
Author(s):  
Emad E. Ghobrial ◽  
Khaled M. Salama ◽  
Maha F. Shiba ◽  
Naglaa H. El Shafae
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Anemia Management
Sign in / Sign up

Export Citation Format

Share Document